• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Medical  Sample 8
 

Medical Sample 8

on

  • 481 views

 

Statistics

Views

Total Views
481
Views on SlideShare
481
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Medical  Sample 8 Medical Sample 8 Presentation Transcript

    • Launch Status 2004 Oct… Dec 2005 Jan… Mar Apr May Jun Jul Aug Sept… Dec 2006 UK Netherlands Norway France Italy Japan Germany Sweden Spain Mexico Finland • Carefully monitoring launches and rapidly sharing learnings across geographies • Japan will launch with hypertension indication
    • EU Launches Leverage US Learnings Reach and 19 CHRs (80% time on 100 PHRs* 2 Hospital frequency Inspra) – Inspra 2 nd position teams – Experienced in 32 IHRs (covering > – Inspra 1st cardiology/hospitals 300 bed hospitals) position – 9 HF nurses – Inspra 1st position Early and HF nurses preparing Extensive AB plan Already on broad hospital patient care pathways and (1000 studies w/5000 nearly all access identifying advocates on patients – all in- hospital D&T committee hospital starts) formularies Urgency to Timing allowed addition of Could not be Launched with treat 30-day data, but it is not incorporated at launch new concept hospitalized the focus – updating the because no publication patient focus in next wave available – updating materials in next wave * Significant distraction due to Lipitor access issues.
    • Current Status • Communication platform refined to establish risk and urgency, focus on hospital initiation • Limited US FF reach and frequency continues to be a challenge • US Launch learnings incorporated into EU Launch plans – Representatives in Ex-US markets selling Inspra in 1st and 2nd position – France doing extensive pre-launch campaign to get on hospital formularies and protocols • Spironolactone comparison is a key issue during details (cost, MOA) • Pricing continues to be an issue in EU